Author of

• 20156

  +

  P1.07 - Immunology and Immunotherapy (ID 693)

  • Event: WCLC 2017
  • Type: Poster Session with Presenters Present
  • Track: Immunology and Immunotherapy
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/16/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)

  • 22669

    +

    P1.07-001 - Clinical Value of Expression of PD-L1 and CD8 of 58 Cases with NSCLC  (ID 7321)

    09:30 - 09:30  |  Author(s): Q. Zhang
    • Abstract

    Background:
    The aim of this study was to classify non-small cell lung cancer (NSCLC) based on the tumor microenvironment (TME) immune status according to the expression of PD-L1(5H1) and infiltration of CD8+ T-cells. To provide effective guidance for patients with NSCLC to use immunotherapy.
    
    Method:
    Fifty-eight patients with NSCLC were enrolled, most of whom are stage I adenocarcinoma. Analyse the expression of PD-L1 and CD8 by immunohistochemistry. According to the tumor microenvironment immune status , we classify the patients into four types: type I (PD-L1+ CD8+), type II (PD-L1-CD8-), type III (PD-L1+CD8-), and type IV (PD-L1-CD8+). Analyze the relationship between the characteristics of patients and the immune status.
    
    Result:
    The positive rate of PD-L1 expressing on the tumor cell is 74.14%(43/58) in 58 cases of NSCLC patients. Whereas the rate of CD8 positive lightly is 60.34%(35/58), the rate of CD8 positive mediately is 29.31%(17/58), and the rate of CD8 positive heavely is 1.72%(1/58). And the rate of type I is 72.41%(42/58), the rate of type II is 6.90%(4/58), the rate of type III is 1.72%(1/58) ,and the rate of type IV is 18.97%(11/58) .
    
    Conclusion:
    The major type of the tumor microenvironment immune status is type I, while the slightest type is type III. Except for the pathological classification (adenocarcinoma, squamous carcinoma, or others) (P < 0.05), we cannot relate the expression of PD - L1 (especially the tumor cell surface expression) to patients' gender, age, and tumor stage (P > 0.05).We conclude the expression of PD-L1 in squamous cell carcinoma is more than that in adenocarinoma ; we also cannot relate tumor infiltration of CD8 + T lymphocytes (none, mild, moderate, severe) with patients' gender, age, pathological classification, and stage (P > 0.05). So we would better test the the expression of the immune bio-marker like PD-L1 which express in the early stage of NSCLC and CD8+ T cell infliction before PD-1 antibody curing in patients of NSCLC to promote the cure rate.